Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.57 |
| ▸ | MYC | P01106 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | AGER | Q15109 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 2/20 | 0.40 |
| ▸ | RBP4 | P02753 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22799826 | 0.84 | ESR2 (0.55) | CAPN1MYCKMT2AKDM4ETDP1 | |
| SCHEMBL541428 | 0.81 | CAPN1 (0.53) | CAPN1TDP1ALDH1A1L3MBTL1TSHR | |
| SCHEMBL22800091 | 0.77 | CAPN1 (0.43) | CAPN1MYCKMT2AKDM4ETDP1 | |
| SCHEMBL9900572 | 0.75 | CAPN1 (0.69) | CAPN1 | |
| SCHEMBL1989647 | 0.74 | MYC (0.49) | CAPN1MYCKMT2AKDM4ETDP1 | |
| SCHEMBL1988242 | 0.74 | MYC (0.49) | MYCKMT2AKDM4ETDP1ALDH1A1 | |
| SCHEMBL1994315 | 0.74 | MYC (0.56) | MYCKMT2AKDM4ETDP1ALDH1A1 | |
| SCHEMBL20028499 | 0.73 | CAPN1 (0.39) | CAPN1KMT2AKDM4EALDH1A1LMNA | |
| Phthalic Acid SCHEMBL5874472 | 0.73 | ALDH1A1 (0.65) | MYCKMT2AKDM4ETDP1ALDH1A1 | |
| Phthalic Acid SCHEMBL5874459 | 0.73 | ALDH1A1 (0.65) | MYCKMT2AKDM4ETDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2648731-B1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V | ABBVIE DEUTSCHLAND (DE) | 2017-01-25 | — | — | EP | disclosed |
| US-9062027-B2 | Carboxamide compounds and their use as calpain inhibitors V | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-23 | — | — | US | disclosed |
| US-9062027-B2 | Carboxamide compounds and their use as calpain inhibitors V | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-23 | — | — | US | disclosed |
| US-20140005227-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-01-02 | — | — | US | disclosed |
| EP-2648731-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V | Abbvie Deutschland GmbH & Co. KG (DE) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012076639-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V | ABBOTT GMBH & CO. KG (DE) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005227-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V | CAPN2, CAPN1, CAPN9 | CAPN1 2/4885MYC 1767/4885KMT2A 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.